These results suggest that Cdc6 may play a more important role in ER positive breast cancer and that breast cancer patients with ER positive status and a low level expression of Cdc6 may have a better prognosis as a result of better response to ER inhibition. This evidence concerns the gene CDC6 and breast carcinoma.